Renuka Iyer

MD
Hematologic Oncology
Image
2022 Buffalo Spree Top Docs badge

Dr. Iyer is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Specializing In:

Bile duct cancer Cholangiocarcinoma Hepatocellular cancer Neuroendocrine cancer Pancreatic cancer Unknown primary cancer

Special Interests:

Develop novel therapies for rare cancer Immunotherapy Biomarkers Quality of life research

About Renuka Iyer

Biography:

I am medical oncologist practicing at Roswell Park with a team of experts who share my passion and commitment to cutting edge quality clinical care and a supportive environment for patients, providers and caregivers to learn and work together to improve outcomes. I do believe in patient centered care, and holistic approaches to treatment. Being involved in many national groups that develop the guidelines and various research grant review committees that help fund cutting edge research I am actively involved in learning and shaping the future of cancer care for the diseases I treat. I look forward to being part of my patients'care team and advocating for them wherever I can.

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Co- Leader Liver and Pancreas Tumor Program
  • Co-Leader GI Translational Research Group
  • Section Chief for Gastrointestinal Oncology, Department of Medicine
  • Vice Chair of Faculty Recruitment & Retention

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Professor of Medicine

Background

Education and Training:

  • 1998 - MD - Grant Medical College, University of Mumbai, Maharashtra, India

Residency:

  • 1998-2001 - Resident - Internal Medicine, Lincoln Medical and Mental Health Center and Cornell University School of Medicine, Bronx, NY

Fellowship:

  • 2004 - Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY
  • 1998 - Post Doctoral Fellowship, Fox Chase Cancer Center, Philadelphia, PA

Board Certification:

  • 2001 - Internal Medicine, American Board of Internal Medicine
  • 2003, 2005 - Medical Oncology, American Board of Internal Medicine

Professional Memberships:

  • Cholangiocarcinoma Foundation
  • Cholangiocarcinoma Foundation - Medical Advisory Board
  • Cholangiocarcinoma Foundation - Nursing Advisory Board
  • NANETs
  • NANETs - Regional Conference Committee Chair
  • Hepatobiliary Cancer Panel, National Comprehensive Cancer Network
  • American Association for Cancer Research
  • Carcinoid.org NET Physician/Expert
  • American Association for the Study of Liver Diseases
  • American College of Gastroenterology
  • American College of Surgeons Oncology Group
  • American Society of Clinical Oncology

Honors & Awards:

  • 2021 - Mark R. Clements Award, for Vision Innovation and Collaboration from the Cholangiocarcinoma Foundation
  • 2018 - Best Teacher Award, Awarded by Roswell Park Comprehensive Cancer Center Medical Oncology Fellows
  • 2008 - Best Teacher Award, Awarded by Roswell Park Comprehensive Cancer Center Medical Oncology Fellows
  • 2006 - American Cancer Society Scholar Award
  • 2003 - Thomas Frawley Resident Research Fellowship award, by State University of New York at Buffalo
  • 2002 - ASCO-AACR Methods in Clinical Cancer Research Workshop Attendee, Vail, CO
  • 1997 - Junior Investigator Award, Tenth International Conference on Chemical Modifiers in Cancer Treatment

Research

Research Overview:

Research interests in phase 1 and 2 clinical trials in GI cancer and animal models research of liver cancer.


Clinical Trials


Featured on Cancer Talk


Publications

Full Publications list on PubMed
  • Kalathil SG, Lugade AA, Miller A, Iyer R, Thanavala Y. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight. 2016 Jul 21;1(11):e86182. doi: 10.1172/jci.insight.86182. PMID: 27540594; PMCID: PMC4986927.
  • Kalathil SG, Lugade AA, Iyer R, Miller A, Thanavala Y. Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. Oncoimmunology. 2016 Sep 20;5(10):e1226718. doi: 10.1080/2162402X.2016.1226718. PMID: 27853648; PMCID: PMC5087301.
  • Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19. PMID: 23423978; PMCID: PMC3645275.